Journal
KIDNEY INTERNATIONAL REPORTS
Volume 3, Issue 4, Pages 771-783Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ekir.2017.12.012
Keywords
acute kidney injury; medical device; selective cytopheretic device; translational medicine
Categories
Funding
- U.S. Army Medical Research and Materiel Command [W81XWH-10-2-0137, W81XWH-11-1-0615, W81XWH-11-1-0730]
- National Institutes of Health [HL118792]
- United States Food and Drug Administration (FDA)
- FDA [1R01 FD 005092, G150179]
- FDA [732168, 1R01FD005092-01] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Regenerative medicine was initially focused on tissue engineering to replace damaged tissues and organs with constructs derived from cells and biomaterials. More recently, this field of inquiry has expanded into exciting areas of translational medicine modulating the body's own endogenous processes, to prevent tissue damage in organs and to repair and regenerate these damaged tissues. This review will focus on recent insights derived from studies in which the manipulation of the innate immunologic system may diminish acute kidney injury and enhance renal repair and recovery without the progression to chronic kidney disease and renal failure. The manner in which these interventions may improve acute and chronic organ dysfunction, including the heart, brain, and lung, will also be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
